JP5284290B2 - ウイルス様粒子の精製 - Google Patents

ウイルス様粒子の精製 Download PDF

Info

Publication number
JP5284290B2
JP5284290B2 JP2009553820A JP2009553820A JP5284290B2 JP 5284290 B2 JP5284290 B2 JP 5284290B2 JP 2009553820 A JP2009553820 A JP 2009553820A JP 2009553820 A JP2009553820 A JP 2009553820A JP 5284290 B2 JP5284290 B2 JP 5284290B2
Authority
JP
Japan
Prior art keywords
vlp
chromatography
vlps
chromatographic
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009553820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530734A (ja
Inventor
ヴェドヴィック,トーマス,エス.
シュテットマン,ブライアン
リチャードソン,チャールズ
フォーベルト,トーマス,アール.
アール. ピートリー,チャールス
Original Assignee
リゴサイト ファーマスーティカルズ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リゴサイト ファーマスーティカルズ,インコーポレイテッド filed Critical リゴサイト ファーマスーティカルズ,インコーポレイテッド
Publication of JP2010530734A publication Critical patent/JP2010530734A/ja
Application granted granted Critical
Publication of JP5284290B2 publication Critical patent/JP5284290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009553820A 2007-03-14 2008-03-14 ウイルス様粒子の精製 Active JP5284290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90682107P 2007-03-14 2007-03-14
US60/906,821 2007-03-14
PCT/US2008/057072 WO2008113011A2 (en) 2007-03-14 2008-03-14 Virus like particle purification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013112580A Division JP2013176392A (ja) 2007-03-14 2013-05-29 ウイルス様粒子の精製

Publications (2)

Publication Number Publication Date
JP2010530734A JP2010530734A (ja) 2010-09-16
JP5284290B2 true JP5284290B2 (ja) 2013-09-11

Family

ID=39760420

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009553820A Active JP5284290B2 (ja) 2007-03-14 2008-03-14 ウイルス様粒子の精製
JP2013112580A Pending JP2013176392A (ja) 2007-03-14 2013-05-29 ウイルス様粒子の精製
JP2017032171A Pending JP2017086090A (ja) 2007-03-14 2017-02-23 ウイルス様粒子の精製
JP2019000688A Pending JP2019068846A (ja) 2007-03-14 2019-01-07 ウイルス様粒子の精製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013112580A Pending JP2013176392A (ja) 2007-03-14 2013-05-29 ウイルス様粒子の精製
JP2017032171A Pending JP2017086090A (ja) 2007-03-14 2017-02-23 ウイルス様粒子の精製
JP2019000688A Pending JP2019068846A (ja) 2007-03-14 2019-01-07 ウイルス様粒子の精製

Country Status (12)

Country Link
US (4) US8481693B2 (enExample)
EP (1) EP2134360B1 (enExample)
JP (4) JP5284290B2 (enExample)
KR (3) KR20150098681A (enExample)
AU (1) AU2008224877B2 (enExample)
CA (1) CA2683977C (enExample)
DK (1) DK2134360T3 (enExample)
ES (1) ES2559421T3 (enExample)
HU (1) HUE028605T2 (enExample)
PL (1) PL2134360T3 (enExample)
SG (2) SG10201701988TA (enExample)
WO (1) WO2008113011A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025022899A (ja) * 2017-12-07 2025-02-14 エーエムペー・バイオテック・ゲーエムベーハー 応用ラジアル技術クロマトグラフィのシステム及び方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641613A1 (en) 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
SG10201701988TA (en) 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
HUE028341T2 (en) * 2009-06-16 2016-12-28 Genzyme Corp Improved methods for purification of recombinant aav vectors
EP2449096A4 (en) * 2009-07-03 2014-01-08 Univ Queensland METHOD FOR PRODUCING A BIOLOGICAL PARTICLE STRUCTURE
US20110142863A1 (en) 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules
EP2524215B1 (en) 2010-01-15 2018-12-26 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
CN102985536B (zh) * 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
WO2012106449A1 (en) 2011-02-02 2012-08-09 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
EP2554664A1 (de) * 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
US9517261B2 (en) * 2011-12-30 2016-12-13 Deutsches Krebsforschungszentrum Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR20150118155A (ko) * 2013-02-22 2015-10-21 에이전시 포 사이언스, 테크놀로지 앤드 리서치 음성 하전된 입자들을 갖는 바이러스 제제들의 크로마토그래피 정제
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Umnファーマ ウイルス様粒子の精製方法
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法
CA2926225A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
EP3157551B1 (en) 2014-06-23 2023-02-15 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN105392569B (zh) 2014-06-23 2019-08-20 生物辐射实验室股份有限公司 磷灰石预处理
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
JP6704074B2 (ja) * 2019-02-04 2020-06-03 株式会社Umnファーマ ウイルス様粒子の精製方法
WO2021002257A1 (ja) * 2019-07-04 2021-01-07 株式会社カネカ ウイルスまたはウイルス様粒子の精製方法
JPWO2022044727A1 (enExample) * 2020-08-28 2022-03-03
JP2023545998A (ja) * 2020-10-05 2023-11-01 ザルトリウス ビーアイエー セパレーションズ ディー.オー.オー. 疎水性相互作用クロマトグラフィーによるdnaプラスミド調製物からのrna及び不純物の改善された除去
JP7621392B2 (ja) * 2021-02-02 2025-01-24 株式会社ニチモ 太陽光発電システム
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
WO2025077800A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Purification of norovirus virus-like particles (vlps)
WO2025077807A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Methods for obtaining high-purity norovirus virus-like particles (vlps)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
AU693203B2 (en) * 1994-05-16 1998-06-25 Merck Sharp & Dohme Corp. Papillomavirus vaccines
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3316325B2 (ja) 1994-12-20 2002-08-19 富士シリシア化学株式会社 ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1998021338A1 (en) 1996-11-08 1998-05-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
AU742409B2 (en) 1997-09-05 2002-01-03 Medimmune, Llc In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
DE19823814A1 (de) * 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
SK2232001A3 (en) * 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
US6349843B1 (en) 1999-04-01 2002-02-26 The Vollrath Company Llc Pan removal ramp
ES2398413T3 (es) * 1999-06-22 2013-03-19 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Kit de detección de SRSV
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2003066021A (ja) 2001-08-28 2003-03-05 Hiroshi Shionoya 連続分取液体クロマトグラフィー装置とそれを用いる方法
AU2003217413A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
DK1501369T3 (en) * 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
CA2496918A1 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US7879338B2 (en) * 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US8277819B2 (en) * 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
CN101389350B (zh) 2005-12-29 2013-11-13 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
AU2007345768B2 (en) 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
EP2641613A1 (en) * 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
SG10201701988TA (en) 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
EP2027875A1 (en) 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
EP2235165A1 (en) 2007-12-21 2010-10-06 Cytos Biotechnology AG Process for clarifying cell homogenates
EP2324113B8 (en) * 2008-08-08 2018-04-04 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
US20110262483A1 (en) 2008-11-03 2011-10-27 Ligocyte Pharmaceuticals, Inc. Methods for isolating enveloped virus-based vlps free of infectious agents
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
KR20120125627A (ko) * 2010-01-21 2012-11-16 리고사이트 파머슈티컬즈 인코퍼레이티드 칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공
US9193760B2 (en) 2010-09-20 2015-11-24 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
FI122520B (fi) 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CN102260651A (zh) 2011-06-24 2011-11-30 华中科技大学同济医学院附属协和医院 一种纯化病毒样颗粒蛋白的方法及其应用
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025022899A (ja) * 2017-12-07 2025-02-14 エーエムペー・バイオテック・ゲーエムベーハー 応用ラジアル技術クロマトグラフィのシステム及び方法

Also Published As

Publication number Publication date
US20160317645A1 (en) 2016-11-03
EP2134360B1 (en) 2015-11-18
US10172930B2 (en) 2019-01-08
EP2134360A4 (en) 2011-08-24
US9359410B2 (en) 2016-06-07
WO2008113011A3 (en) 2008-12-24
US8481693B2 (en) 2013-07-09
EP2134360A2 (en) 2009-12-23
CA2683977C (en) 2017-04-25
KR20150098681A (ko) 2015-08-28
US20190282686A1 (en) 2019-09-19
WO2008113011A2 (en) 2008-09-18
JP2017086090A (ja) 2017-05-25
KR20100015562A (ko) 2010-02-12
DK2134360T3 (en) 2016-02-22
SG10201701988TA (en) 2017-04-27
JP2019068846A (ja) 2019-05-09
US20100150961A1 (en) 2010-06-17
AU2008224877A1 (en) 2008-09-18
HK1138795A1 (zh) 2010-09-03
HUE028605T2 (en) 2016-12-28
ES2559421T3 (es) 2016-02-12
SG179488A1 (en) 2012-04-27
KR20170001720A (ko) 2017-01-04
US20130344107A1 (en) 2013-12-26
CA2683977A1 (en) 2008-09-18
JP2013176392A (ja) 2013-09-09
JP2010530734A (ja) 2010-09-16
AU2008224877B2 (en) 2013-07-11
KR101576219B1 (ko) 2015-12-10
US10792353B2 (en) 2020-10-06
PL2134360T3 (pl) 2016-05-31

Similar Documents

Publication Publication Date Title
JP5284290B2 (ja) ウイルス様粒子の精製
Li et al. A hydrophobic interaction chromatography strategy for purification of inactivated foot-and-mouth disease virus
US10570376B2 (en) Method for influenza virus purification
JP2007523621A (ja) ウイルスを精製するための方法
JP7540667B2 (ja) アデノウイルス精製の方法
CN105018435A (zh) 一种病毒样颗粒的纯化方法
Chen et al. Purification of capsid-like particles of infectious bursal disease virus (IBDV) VP2 expressed in E. coli with a metal-ion affinity membrane system
AU2013242822B2 (en) Virus like particle purification
JP7586936B2 (ja) 混入dnaをより効果的に除去するための、アデノ随伴ウイルスの精製の強化
AU2016269506A1 (en) Virus like particle purification
HK1138795B (en) Virus like particle purification
JP2024004020A (ja) A型肝炎ウイルスのクロマトグラフィー精製方法
JP4706093B2 (ja) パルボウイルスの除去方法及び精製方法
Cornelissen et al. CIM® monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130529

R150 Certificate of patent or registration of utility model

Ref document number: 5284290

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250